Olanzapine, Amantadine + Olanzapine and placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Psychotic Disorder
Conditions
Psychotic Disorder, Schizophreniform Disorder, Schizophrenia, Schizoaffective Disorder, Mood Disorders With Psychotic Features
Trial Timeline
May 1, 2005 → Sep 1, 2009
NCT ID
NCT00287352About Olanzapine, Amantadine + Olanzapine and placebo
Olanzapine, Amantadine + Olanzapine and placebo is a phase 1 stage product being developed by Eli Lilly for Psychotic Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00287352. Target conditions include Psychotic Disorder, Schizophreniform Disorder, Schizophrenia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00287352 | Phase 1 | Completed |
Competing Products
14 competing products in Psychotic Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| risperidone IR and LAI formulation | Johnson & Johnson | Phase 1 | 33 |
| quetiapine | AstraZeneca | Phase 3 | 77 |
| Quetiapine | AstraZeneca | Phase 3 | 77 |
| Quetiapine | AstraZeneca | Phase 3 | 77 |
| quetiapine + olanzapine + risperidone | AstraZeneca | Pre-clinical | 23 |
| Asenapine 5-20 mg daily + Placebo 1-4 tablets daily | Merck | Approved | 85 |
| Ziprasidone HCL (oral) | Pfizer | Approved | 84 |
| Aripiprazole | Bristol Myers Squibb | Phase 3 | 76 |
| Aripiprazole + Risperidone/Quetiapine | Bristol Myers Squibb | Pre-clinical | 22 |
| mifepristone + placebo | Corcept Therapeutics | Phase 3 | 72 |
| Miricorlilant + Miricorlilant + Placebo | Corcept Therapeutics | Phase 2 | 47 |
| Miricorilant + Fluvoxamine | Corcept Therapeutics | Phase 1 | 28 |
| Miricorilant + Placebo | Corcept Therapeutics | Phase 2 | 47 |
| Olanzapine + CORT118335 + Placebo | Corcept Therapeutics | Phase 1 | 28 |